Cannabis & health – side effects, honestly explained

What is reliably known about the health effects

The discussion surrounding cannabis and health suffers from the fact that both camps make absolute claims. A sober assessment is more nuanced. In the short term, the effects are well-documented: impairment of short-term memory, attention, and reaction time, increased heart rate, and, at higher doses, anxiety and restlessness. These effects subside as the effects wear off.

Regarding long-term risks, the data is robust in some areas and open in others. Robust findings include the link between early and regular use during adolescence and unfavourable outcomes — the developing brain is more sensitive — as well as an increased risk of psychotic disorders in individuals with a genetic predisposition and high-dose consumption. The potential for dependence is also well-documented: a significant proportion of regular users develop a cannabis use disorder.

Questions regarding long-term cognitive effects in adults after ceasing use and the respiratory effects of vaporising remain more open. Anyone looking for a reliable assessment should differentiate studies by consumption pattern, age of onset, and dose — statements without this differentiation are rarely reliable.

• Short-term: memory, attention, reaction time, heart rate
• Adolescents: increased risk because brain development is still ongoing
• Psychoses: increased risk in case of predisposition and high-dose consumption
• Dependence: real, more common with daily consumption and early onset

Reducing risk — and when professional help is useful

Those who consume can significantly influence their risk profile. The most effective levers are: delaying the onset of consumption until adulthood, limiting frequency, avoiding high-dose products, not mixing with tobacco, and replacing combustion with vaporisation. Anyone with pre-existing mental health conditions or a family history of psychosis should avoid THC — this is the clearest single recommendation that can be derived from the available data.

Legally, the 1% threshold for total THC applies in Switzerland. The decisive factor is always the total THC, i.e. THC plus THCA multiplied by the factor 0.877. A product with 0.4% delta-9-THC and 0.9% THCA has around 1.19% total THC and is therefore a narcotic — even if the packaging says «under 1%». Medical cannabis has been prescribable by doctors without a BAG exceptional permit since 1 August 2022; however, cost coverage by health insurance is not automatically regulated and is assessed on a case-by-case basis.

These pages do not replace medical advice. In the event of distressing symptoms, loss of control, or the desire to quit, family doctors, cantonal addiction advisory services, or Safe Zone are the right contact points; in case of acute poisoning, contact Tox Info Suisse on 145, and in emergencies, 144.

Structure of this cluster

The subpages cover the effects on the brain and cognition, respiratory tract, cardiovascular system, mental health, dependence and withdrawal, consumption during pregnancy, as well as adolescents and risk groups.

Anyone who is worried about their own consumption will find concrete indications and contact points on the page on dependence and withdrawal — much more useful than a general list of risks.

Legal classification and consumer protection

In Switzerland, the total THC value determines whether a product is classified as a narcotic. If this value, which is composed of delta-9-THC and THCA multiplied by a factor of 0.877, is below one percent, handling it is legal. This clear limit protects consumers from illegal substances, ensures the protection of minors, and enables quality control by the Federal Office of Public Health (BAG) and the Federal Food Safety and Veterinary Office (BLV). For consumers, this regulation provides a reliable guide regarding active ingredient concentration.

On the other hand, anyone who consumes products with a higher THC content is operating in the illegal sphere, unless this occurs within the framework of medical care or scientific projects. The illegal market carries significant health risks, as contaminants or synthetic cutting agents are not subject to official controls. Adults face a fixed penalty fine (Ordnungsbusse) for minor possession for personal consumption, while the protection of minors provides for stricter measures. The distinction between legal CBD cannabis and illegal THC cannabis is therefore of central importance both for legal certainty and for health self-protection.

• Total THC limit of less than one percent separates legal from illegal products.
• Official monitoring by the BAG and BLV ensures quality in the legal segment.
• Danger of unregulated contaminants and unclear active ingredient levels on the black market.
• Fixed penalty procedures for minor infractions in the illegal sector.

Road traffic and the Swiss zero-tolerance policy

Participating in road traffic requires full concentration, which is why a strict zero-tolerance practice regarding THC applies in Switzerland. The legal detection limit in blood is a mere 1.5 micrograms per litre. Since THC is metabolised irregularly in the body and accumulates in adipose tissue, this limit can be exceeded even days after the last consumption. Anyone who reaches or exceeds this limit is legally deemed absolutely unfit to drive, which entails far-reaching legal and financial consequences.

From a health perspective, the impairment of reaction time and spatial perception after consumption is well documented. The combination of slowed information processing and misjudgements significantly increases the risk of accidents. Consumers often underestimate how long the psychoactive effect lasts and how slow the elimination process is. A strict separation of consumption and driving is therefore the only reliable method to prevent serious accidents and avoid jeopardising one's driving licence.

• Strict limit of 1.5 micrograms of THC per litre of blood in road traffic.
• Detectability in the blood is often still present days after the actual consumption.
• Increased risk of accidents due to delayed reaction time and impaired perception.
• Legal unfitness to drive applies regardless of the subjective feeling of sobriety.

Scientific pilot trials for harm reduction

In order to test new approaches to handling cannabis, Switzerland has created the legal basis for scientific pilot trials. According to the Narcotics Act, cities and cantons can carry out time-limited projects such as Züri Can, Weed Care in Basel or the SCRIPT project. These trials investigate how a regulated sale of cannabis affects the health of participants and the black market. The scientific monitoring is intended to provide sound data to place future Swiss cannabis policy on an evidence-based foundation.

Through controlled purchasing in pharmacies or special points of sale, participants gain access to products with a known active ingredient content and without harmful adulterants. In addition, an obligatory consultation takes place at the time of purchase, aiming at risk minimisation and the protection of minors. Initial findings from these projects are intended to show whether a regulated market can help reduce health risks compared to uncontrolled consumption from the black market. The trials are closely coordinated with the cantonal health authorities and the BAG.

• Scientific pilot projects such as Züri Can and Weed Care Basel are time-limited.
• Regulated sales enable seamless quality control and known active ingredient strengths.
• Integrated advisory services directly at the points of sale promote low-risk consumption.
• Obtaining scientific data for future Swiss legislation.

Medical cannabis in the Swiss healthcare system

Since the amendment of the law in August 2022, access to medical cannabis in Switzerland has been significantly simplified. Doctors can now prescribe corresponding preparations directly and without a time-consuming exceptional permit from the Federal Office of Public Health (FOPH). This facilitation is primarily aimed at patients with chronic pain, spasticity or other severe symptoms for whom conventional therapies do not provide sufficient relief. The prescription requirement ensures that use takes place under professional medical supervision.

Although the barrier to prescription has been lowered, cost coverage by health insurance funds remains a complex issue. The compulsory health insurance does not cover the costs automatically, but decides on a case-by-case basis upon application by the treating physician. Swissmedic monitors the quality and approval of medical products to guarantee a consistent active ingredient concentration and purity. Patients should always discuss the therapeutic options and cost clarification in detail with their doctor's office in advance.

• Direct medical prescription of medical cannabis without an FOPH exceptional permit since August 2022.
• Areas of application primarily include chronic pain and neurological diseases.
• Cost coverage by health insurance only takes place after an individual case-by-case review.
• Quality assurance and monitoring of medical preparations by Swissmedic.

FAQ